REVELATION BIOSCIENCES, INC. (REVB)

Data as of Aug 18, 2026, from SEC Form 4 filings.

No open-market insider trades (90d)Watch REVB

See up to 3 months of REVB. The 7-day demo opens the 1M and 3M ranges and puts REVB on your watchlist.

Latest REVB insider trades

James Rolke - Officer
Grant or award208,076 sh
Aug 17, 2026
Lakhmir S. Chawla - Director
Grant or award32,011 sh
Aug 17, 2026
Chester Stanley Zygmont III - Officer
Grant or award

About REVELATION BIOSCIENCES, INC. (REVB)

REVELATION BIOSCIENCES, INC. files with the SEC under CIK 0001810560 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.

Sector: Health Care

SEC filings for REVB on EDGAR

REVB Form 4 activity by transaction type, last 90 days

Form 4 transaction type	Transactions	Shares	Total value
Grant or award	5	512,182
Bona-fide gift	2	416,146

Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.

REVB insider transactions (Form 4)

22 Form 4 filings on record, the earliest from Oct 31, 2025, newest first.

Date	Insider	Transaction	Security	Shares	Price	Value
Aug 17, 2026	James Rolke - Officer	Grant or award	Common Stock	208,076^{footnote F1}	$0.00	-
Footnote F1 (shares): These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary… Full note on SEC EDGAR
Aug 17, 2026	Lakhmir S. Chawla - Director	Grant or award	Common Stock	32,011^{footnote F1}	$0.00	-
Footnote F1 (shares): These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary… Full note on SEC EDGAR
Aug 17, 2026	Chester Stanley Zygmont III - Officer	Grant or award	Common Stock	208,073^{footnote F1}	$0.00	-
Aug 17, 2026	Chester Stanley Zygmont III - Officer	Gift	Common Stock	208,073^{footnote F1}	$0.00	-
Aug 17, 2026	Chester Stanley Zygmont III - Officer	Gift	Common Stock	208,073^{footnote F1}	$0.00	-
Footnote F1 (shares): These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary… Full note on SEC EDGAR
Aug 17, 2026	Jess Roper - Director	Grant or award	Common Stock	32,011^{footnote F1}	$0.00	-
Footnote F1 (shares): These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary… Full note on SEC EDGAR
Aug 17, 2026	Jennifer Carver - Director	Grant or award	Common Stock	32,011^{footnote F1}	$0.00	-
Footnote F1 (shares): These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary… Full note on SEC EDGAR
Apr 30, 2026	James Rolke - Officer	Tax withholding / forfeiture	Common Stock	10,115^{footnote F1}	$1.13^{footnote F2}	$11K
Footnote F1 (shares): Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with… Full note on SEC EDGAR Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.14, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the… Full note on SEC EDGAR
Apr 30, 2026	Chester Stanley Zygmont III - Officer	Tax withholding / forfeiture	Common Stock	13,285^{footnote F1}	$1.10^{footnote F2}	$15K
Footnote F1 (shares): Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with… Full note on SEC EDGAR Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.09 to $1.13, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the… Full note on SEC EDGAR
Feb 3, 2026	Jess Roper	Tax withholding / forfeiture	Common Stock	1,591^{footnote F1,F2}	$1.85^{footnote F3}	$3K
Footnote F1 (shares): All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. Footnote F2 (shares): Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to… Full note on SEC EDGAR Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the… Full note on SEC EDGAR
Feb 3, 2026	Lakhmir S. Chawla	Tax withholding / forfeiture	Common Stock	2,261^{footnote F1,F2}	$1.85^{footnote F3}	$4K
Footnote F1 (shares): All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. Footnote F2 (shares): Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to… Full note on SEC EDGAR Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the… Full note on SEC EDGAR
Feb 3, 2026	Jennifer Carver	Tax withholding / forfeiture	Common Stock	1,661^{footnote F1,F2}	$1.87^{footnote F3}	$3K
Footnote F1 (shares): All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. Footnote F2 (shares): Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to… Full note on SEC EDGAR Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the… Full note on SEC EDGAR
Feb 3, 2026	James Rolke - Officer	Tax withholding / forfeiture	Common Stock	8,521^{footnote F1,F2}	$1.86^{footnote F3}	$16K
Footnote F1 (shares): All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. Footnote F2 (shares): Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with… Full note on SEC EDGAR Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the… Full note on SEC EDGAR
Feb 4, 2026	Chester Stanley Zygmont III - Officer	Tax withholding / forfeiture	Common Stock	13,100^{footnote F1,F2}	$1.65^{footnote F3}	$22K
Footnote F1 (shares): All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. Footnote F2 (shares): Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with… Full note on SEC EDGAR Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.63 to $1.66, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the… Full note on SEC EDGAR
Jan 8, 2026	James Rolke - Officer	Grant or award	Common Stock	532,829	$0.90	$480K
Jan 8, 2026	Chester Stanley Zygmont III - Officer	Grant or award	Common Stock	78,145	$0.90	$70K
Jan 8, 2026	Jennifer Carver	Grant or award	Common Stock	41,981	$0.90	$38K
Jan 8, 2026	Jess Roper	Grant or award	Common Stock	41,981	$0.90	$38K
Jan 8, 2026	Lakhmir S. Chawla	Grant or award	Common Stock	41,981	$0.90	$38K
Oct 29, 2025	Chester Stanley Zygmont III - Officer	Grant or award	Common Stock	390,614	$1.28	$500K
Oct 29, 2025	James Rolke - Officer	Grant or award	Common Stock	390,614	$1.28	$500K
Oct 29, 2025	Jennifer Carver	Grant or award	Common Stock	15,625	$1.28	$20K
Oct 29, 2025	Lakhmir S. Chawla	Grant or award	Common Stock	15,625	$1.28	$20K
Oct 29, 2025	Jess Roper	Grant or award	Common Stock	15,625	$1.28	$20K

Recent REVB Form 8-K filings

Read REVB company news

Aug 19, 2026Item 5.02, 9.01

Read the filing on SEC EDGAR

Aug 6, 2026Item 2.02, 9.01

Read the filing on SEC EDGAR

Jul 13, 2026Item 1.01, 3.03, 5.03, 7.01, 9.01

Read the filing on SEC EDGAR

Jun 24, 2026Item 5.02, 5.03, 5.07, 9.01

REVB insider trading FAQ

What is the latest insider trade for REVB?

REVELATION BIOSCIENCES, INC. (REVB) had 5 insider filings in the last 90 days, with the most recent on 2026-08-18. The full record for REVB runs to 22 Form 4 filings, the earliest from 2025-10-31. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying REVB stock?

No insider purchases of REVB were filed in the last 90 days.

How many insiders are selling REVB stock?

No insider sales of REVB were filed in the last 90 days.

Where can I see REVB SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects REVB Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Aug 18, 2026 - James Rolke view on EDGAR
Aug 18, 2026 - Lakhmir S. Chawla view on EDGAR
Aug 18, 2026 - Chester Stanley Zygmont III view on EDGAR
Aug 18, 2026 - Jess Roper view on EDGAR
Aug 18, 2026 - Jennifer Carver view on EDGAR
May 1, 2026 - James Rolke view on EDGAR
May 1, 2026 - Chester Stanley Zygmont III view on EDGAR
Feb 5, 2026 - Jess Roper view on EDGAR
Feb 5, 2026 - Lakhmir S. Chawla view on EDGAR

Related companies with recent insider activity

Learn more

What the Form 4 transaction codes mean: Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
Insider activity in Health Care: Where REVB's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow REVB with a 7-day demo

REVB on your watchlist
Every REVB Form 4 filing on record
Up to 3 months of REVB price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Form 4 transaction type

Transactions

Total value

Grant or award

512,182

Bona-fide gift

416,146

Date

Insider

Transaction

Security

Price

Value

Aug 17, 2026

James Rolke - Officer

Grant or award

Common Stock

208,076^{footnote F1}

$0.00

Footnote F1 (shares): These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary… Full note on SEC EDGAR

Aug 17, 2026

Lakhmir S. Chawla - Director

Grant or award

Common Stock

32,011^{footnote F1}

$0.00

Footnote F1 (shares): These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary… Full note on SEC EDGAR

Aug 17, 2026

Chester Stanley Zygmont III - Officer

Grant or award

Common Stock

208,073^{footnote F1}

$0.00

Aug 17, 2026

Chester Stanley Zygmont III - Officer

Gift

Common Stock

208,073^{footnote F1}

$0.00

Aug 17, 2026

Chester Stanley Zygmont III - Officer

Gift

Common Stock

208,073^{footnote F1}

$0.00

Footnote F1 (shares): These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary… Full note on SEC EDGAR

Aug 17, 2026

Jess Roper - Director

Grant or award

Common Stock

32,011^{footnote F1}

$0.00

Footnote F1 (shares): These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary… Full note on SEC EDGAR

Aug 17, 2026

Jennifer Carver - Director

Grant or award

Common Stock

32,011^{footnote F1}

$0.00

Footnote F1 (shares): These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary… Full note on SEC EDGAR

Apr 30, 2026

James Rolke - Officer

Tax withholding / forfeiture

Common Stock

10,115^{footnote F1}

$1.13^{footnote F2}

$11K

Footnote F1 (shares): Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.14, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the… Full note on SEC EDGAR

Apr 30, 2026

Chester Stanley Zygmont III - Officer

Tax withholding / forfeiture

Common Stock

13,285^{footnote F1}

$1.10^{footnote F2}

$15K

Footnote F1 (shares): Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with… Full note on SEC EDGAR
Footnote F2 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.09 to $1.13, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the… Full note on SEC EDGAR

Feb 3, 2026

Jess Roper

Tax withholding / forfeiture

Common Stock

1,591^{footnote F1,F2}

$1.85^{footnote F3}

$3K

Footnote F1 (shares): All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.
Footnote F2 (shares): Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to… Full note on SEC EDGAR
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the… Full note on SEC EDGAR

Feb 3, 2026

Lakhmir S. Chawla

Tax withholding / forfeiture

Common Stock

2,261^{footnote F1,F2}

$1.85^{footnote F3}

$4K

Footnote F1 (shares): All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.
Footnote F2 (shares): Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to… Full note on SEC EDGAR
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the… Full note on SEC EDGAR

Feb 3, 2026

Jennifer Carver

Tax withholding / forfeiture

Common Stock

1,661^{footnote F1,F2}

$1.87^{footnote F3}

$3K

Footnote F1 (shares): All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.
Footnote F2 (shares): Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to… Full note on SEC EDGAR
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the… Full note on SEC EDGAR

Feb 3, 2026

James Rolke - Officer

Tax withholding / forfeiture

Common Stock

8,521^{footnote F1,F2}

$1.86^{footnote F3}

$16K

Footnote F1 (shares): All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.
Footnote F2 (shares): Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with… Full note on SEC EDGAR
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the… Full note on SEC EDGAR

Feb 4, 2026

Chester Stanley Zygmont III - Officer

Tax withholding / forfeiture

Common Stock

13,100^{footnote F1,F2}

$1.65^{footnote F3}

$22K

Footnote F1 (shares): All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.
Footnote F2 (shares): Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with… Full note on SEC EDGAR
Footnote F3 (price): The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.63 to $1.66, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the… Full note on SEC EDGAR

Jan 8, 2026

James Rolke - Officer

Grant or award

Common Stock

532,829

$0.90

$480K

Jan 8, 2026

Chester Stanley Zygmont III - Officer

Grant or award

Common Stock

78,145

$0.90

$70K

Jan 8, 2026

Jennifer Carver

Grant or award

Common Stock

41,981

$0.90

$38K

Jan 8, 2026

Jess Roper

Grant or award

Common Stock

41,981

$0.90

$38K

Jan 8, 2026

Lakhmir S. Chawla

Grant or award

Common Stock

41,981

$0.90

$38K

Oct 29, 2025

Chester Stanley Zygmont III - Officer

Grant or award

Common Stock

390,614

$1.28

$500K

Oct 29, 2025

James Rolke - Officer

Grant or award

Common Stock

390,614

$1.28

$500K

Oct 29, 2025

Jennifer Carver

Grant or award

Common Stock

15,625

$1.28

$20K

Oct 29, 2025

Lakhmir S. Chawla

Grant or award

Common Stock

15,625

$1.28

$20K

Oct 29, 2025

Jess Roper

Grant or award

Common Stock

15,625

$1.28

$20K